After Pfizer and Moderna, this company`s COVID-19 vaccine shows 70% efficacy

Grant Boone
November 23, 2020

The trial looked at two different dosing regimens - a half dose of the vaccine followed by a full dose at least one month apart was 90 per cent effective.

Serum Institute CEO had at the HT Leadership Summit on Thursday said the company plans to apply for an emergency use authorisation from the Drug Controller General of India V.G. Somani for its vaccine next month, and get the regulatory greenlight in January, provided there was robust efficacy data from Astrazeneca's trials. All results were statistically significant.

Oxford-AstraZeneca, however, added that the efficacy of vaccine could be around 90 per cent under one dosing regimen.

AstraZeneca chief executive Pascal Soriot said his firm's vaccine would still be highly effective and would have an "immediate impact".

The British drugmaker's preliminary trial results mark a fresh breakthrough in the fight against a pandemic that has killed almost 1.4 million people and roiled the global economy.

The data comes after United States rivals published interim data in recent weeks showing efficacy of more than 90%.

It is hoped a Covid vaccine could help to bring an end to the coronavirus pandemic that has claimed more than 1.3 million lives worldwide.

Sei Young Kim wins 2nd title of season at Pelican Women's Championship
Popov had lit up the course on Thursday with a six-under-par 66 when she pocketed six birdies on the front nine alone. She made substantially more money ($675,000) for that single victory than she had in her entire LPGA career.

Pfizer said in official statement that that its coronavirus vaccine has shown 95 per cent efficacy in the late-stage trial.

The results ranged between 62 and 90 percent efficacy depending on the vaccine dosage, according to Monday's statement. The vaccine can also be administered within existing healthcare settings such as hospitals and doctors.

The Oxford vaccine is already in its third and final phase of clinical trials in India, and if all things go as planned, the COVID-19 vaccine may be ready for distribution by January or February 2021.

Meanwhile, Moderna also announced that its Covid-19 vaccine was 94.5 per cent effective in preventing coronavirus. He pointed out that the primary outcome for these vaccine trials is simply a laboratory-confirmed case of infection with SARS-CoV2, with at least one symptom - which could be as mild as a cough, fever or diarrhoea. Public health experts said the world will need many vaccines to meet global demand.

The researchers said this figure could change as the final results of the trial are analysed, but added that they would be applying for fast-track approval. No hospitalizations or severe cases of the disease were reported in participants receiving the vaccine. The trials are also not created to measure whether they reduce illness in those at greater risk, such as the elderly, or those with comorbidities.

While the other two vaccines have to be stored frozen, the Astra-Oxford jab can be kept at refrigerator temperature, which would make it easier to transport and store globally, particularly in lower and middle-income countries.

Other reports by

Discuss This Article